Compare Divis Laboratories with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs DISHMAN PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES DISHMAN PHARMA DIVIS LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x 50.9 25.1 203.1% View Chart
P/BV x 13.6 3.3 407.1% View Chart
Dividend Yield % 0.4 0.7 67.5%  

Financials

 DIVIS LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639374 437.8%   
Low Rs1,115129 865.0%   
Sales per share (Unadj.) Rs186.3197.8 94.2%  
Earnings per share (Unadj.) Rs51.021.2 240.3%  
Cash flow per share (Unadj.) Rs57.334.7 165.1%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.8 146.2%  
Book value per share (Unadj.) Rs261.8179.9 145.5%  
Shares outstanding (eoy) m265.4780.69 329.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.41.3 581.0%   
Avg P/E ratio x27.011.9 227.7%  
P/CF ratio (eoy) x24.07.2 331.5%  
Price / Book Value ratio x5.31.4 376.1%  
Dividend payout %31.49.4 332.9%   
Avg Mkt Cap Rs m365,59220,306 1,800.4%   
No. of employees `00011.80.8 1,429.1%   
Total wages/salary Rs m5,4235,355 101.3%   
Avg. sales/employee Rs Th4,175.119,252.7 21.7%   
Avg. wages/employee Rs Th457.76,459.5 7.1%   
Avg. net profit/employee Rs Th1,141.82,064.1 55.3%   
INCOME DATA
Net Sales Rs m49,46315,961 309.9%  
Other income Rs m1,556265 586.4%   
Total revenues Rs m51,01916,226 314.4%   
Gross profit Rs m18,7184,103 456.2%  
Depreciation Rs m1,6891,091 154.9%   
Interest Rs m35944 3.7%   
Profit before tax Rs m18,5512,334 794.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023624 805.5%   
Profit after tax Rs m13,5271,711 790.6%  
Gross profit margin %37.825.7 147.2%  
Effective tax rate %27.126.7 101.3%   
Net profit margin %27.310.7 255.1%  
BALANCE SHEET DATA
Current assets Rs m46,50111,018 422.0%   
Current liabilities Rs m8,4689,517 89.0%   
Net working cap to sales %76.99.4 817.7%  
Current ratio x5.51.2 474.4%  
Inventory Days Days131110 118.4%  
Debtors Days Days8635 246.4%  
Net fixed assets Rs m25,79716,304 158.2%   
Share capital Rs m531161 328.9%   
"Free" reserves Rs m68,96212,907 534.3%   
Net worth Rs m69,49314,516 478.8%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m80,38329,805 269.7%  
Interest coverage x531.03.5 15,298.8%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %16.98.9 189.4%  
Return on equity %19.511.8 165.1%  
Return on capital %26.717.5 152.6%  
Exports to sales %024.8 0.0%   
Imports to sales %24.63.7 659.5%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs m12,187596 2,043.7%   
Fx inflow Rs m41,2384,952 832.8%   
Fx outflow Rs m12,405697 1,780.3%   
Net fx Rs m28,8334,255 677.7%   
CASH FLOW
From Operations Rs m9,5432,786 342.5%  
From Investments Rs m-6,854-1,529 448.3%  
From Financial Activity Rs m-2,459-941 261.3%  
Net Cashflow Rs m230316 72.6%  

Share Holding

Indian Promoters % 52.0 61.4 84.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 3.7 318.9%  
FIIs % 19.0 12.7 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 22.1 77.8%  
Shareholders   31,796 46,261 68.7%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  WYETH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 101 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 385 points, down 0.8% at 51,059 levels.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Mar 4, 2021 03:02 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS